Free Trial

Travere Therapeutics (TVTX) Competitors

Travere Therapeutics logo
$14.84 +0.13 (+0.88%)
Closing price 04:00 PM Eastern
Extended Trading
$14.95 +0.11 (+0.77%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TVTX vs. AXSM, AKRO, PCVX, ADMA, PTCT, RYTM, CYTK, KRYS, ZLAB, and ACAD

Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Vaxcyte (PCVX), ADMA Biologics (ADMA), PTC Therapeutics (PTCT), Rhythm Pharmaceuticals (RYTM), Cytokinetics (CYTK), Krystal Biotech (KRYS), Zai Lab (ZLAB), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

Travere Therapeutics vs. Its Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Axsome Therapeutics has a net margin of -64.39% compared to Travere Therapeutics' net margin of -82.88%. Axsome Therapeutics' return on equity of -272.80% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-64.39% -272.80% -36.69%
Travere Therapeutics -82.88%-1,179.73%-41.10%

In the previous week, Travere Therapeutics had 2 more articles in the media than Axsome Therapeutics. MarketBeat recorded 8 mentions for Travere Therapeutics and 6 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.80 beat Travere Therapeutics' score of 0.42 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Travere Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Axsome Therapeutics presently has a consensus target price of $172.33, suggesting a potential upside of 65.85%. Travere Therapeutics has a consensus target price of $32.14, suggesting a potential upside of 116.60%. Given Travere Therapeutics' higher possible upside, analysts clearly believe Travere Therapeutics is more favorable than Axsome Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
3.06
Travere Therapeutics
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87

Axsome Therapeutics has higher revenue and earnings than Travere Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$385.69M13.27-$287.22M-$5.77-18.01
Travere Therapeutics$233.18M5.65-$321.55M-$2.81-5.28

Axsome Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

81.5% of Axsome Therapeutics shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.1% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Axsome Therapeutics beats Travere Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Travere Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVTX vs. The Competition

MetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.32B$2.90B$5.49B$8.93B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio-5.2821.2626.2019.89
Price / Sales5.65279.34415.50166.23
Price / CashN/A41.8936.4957.06
Price / Book19.537.508.055.39
Net Income-$321.55M-$55.05M$3.15B$248.50M
7 Day Performance-0.67%2.49%1.92%2.96%
1 Month Performance-4.38%7.40%4.90%6.02%
1 Year Performance83.44%5.42%35.95%20.44%

Travere Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVTX
Travere Therapeutics
3.1806 of 5 stars
$14.84
+0.9%
$32.14
+116.6%
+77.7%$1.32B$233.18M-5.28460Analyst Forecast
AXSM
Axsome Therapeutics
4.6726 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+27.1%$4.96B$385.69M-17.62380Analyst Revision
AKRO
Akero Therapeutics
3.6155 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+122.0%$4.32BN/A-27.7130
PCVX
Vaxcyte
1.7882 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-57.2%$4.24BN/A-8.33160News Coverage
Positive News
ADMA
ADMA Biologics
4.0895 of 5 stars
$17.87
+0.7%
$27.67
+54.8%
+54.8%$4.24B$426.45M21.02530
PTCT
PTC Therapeutics
4.4113 of 5 stars
$49.60
-1.2%
$65.00
+31.0%
+55.9%$3.98B$806.78M7.621,410Analyst Revision
Gap Down
RYTM
Rhythm Pharmaceuticals
3.8956 of 5 stars
$62.13
+0.2%
$76.62
+23.3%
+53.4%$3.94B$130.13M-22.11140
CYTK
Cytokinetics
4.2833 of 5 stars
$32.64
+0.6%
$70.92
+117.3%
-38.5%$3.87B$18.47M-6.17250Positive News
KRYS
Krystal Biotech
4.6181 of 5 stars
$137.92
+4.1%
$211.13
+53.1%
-23.7%$3.83B$290.52M33.15210Analyst Revision
High Trading Volume
ZLAB
Zai Lab
3.3837 of 5 stars
$36.01
+4.2%
$47.37
+31.5%
+103.4%$3.81B$398.99M-14.461,869Analyst Forecast
Insider Trade
Analyst Revision
ACAD
ACADIA Pharmaceuticals
4.6866 of 5 stars
$22.48
-1.0%
$27.64
+23.0%
+33.2%$3.80B$957.80M16.41510

Related Companies and Tools


This page (NASDAQ:TVTX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners